Topic: How To Invest

What is Pat’s commentary for the week of November 24, 2020

Article Excerpt

In the weeks since the U.S. Presidential election, several of 2020’s main investor concerns have begun to fade. Gains in the medical fight against COVID-19 The U.S. Food and Drug Administration (FDA) authorized emergency use of Regeneron’s COVID-19 antibody drug. It cleared this antibody drug cocktail for use in treating mild-to-moderate COVID-19 patients 12 years of age and up, including people older than 65. (This, by the way, is one of three experimental drug treatments that White House doctors used on President Trump in October, when he tested positive for COVID during the election campaign.) In the week after the election, the FDA authorized use for Eli Lilly’s bamlanivimab, another antibody COVID treatment. Both the Regeneron and Lilly drugs are examples of monoclonal antibodies. In 1908, Dr. Paul Ehrlich won the Nobel Prize for his work in immunology. A year later, he discovered a cure for syphilis. Dr. Ehrlich postulated that science would one day create a “magic bullet” that could selectively target a..